The CAFC’s Amgen v Sanofi decision spells trouble for broad functional patent claims
The CAFC’s much-anticipated ruling has major implications for antibody patents and continues the court’s trend of imposing a tough enablement standard for genus claims
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.